An Observational Study of Statin Treatment Induced HDL Changes
NCT ID: NCT01551784
Last Updated: 2013-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120000 participants
OBSERVATIONAL
2012-03-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Short-term Intensive Statin Therapy on Lipid Levels
NCT07344610
Effective Dose of Statin Post PCI
NCT04923152
Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)
NCT01245738
Observational Study to Estimate the Rates of Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) With Drug Eluting Stent (DES) Implantation Who Take Statins
NCT01047176
The Effect on EPCs by Statin Loading in "All Comers" With an ACS
NCT02957162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must have valid baseline and follow-up measurements for HDL-C and LDL-C.
Exclusion Criteria
18 Years
86 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gunnar Johansson, MD, PROFESSOR
Role: PRINCIPAL_INVESTIGATOR
Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology Uppsala University 751 22 Uppsala Sweden
Ron Herings, DR, ASSOC PROF
Role: PRINCIPAL_INVESTIGATOR
Pharmo Institute for Drug Outcomes Research3508 AE UtrechtThe Netherlands
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CSE-CRE-2011/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.